About Mankind Pharma Limited
Data last updated: 09 January 2026
Mankind Pharma Limited is a public limited company based in New Delhi, Delhi, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 03 July 1991, the company has been in operation for over 35 years.
Registered with ROC Delhi under CIN L74899DL1991PLC044843. Listed.
Capital: an authorised share capital of ₹421.51 Cr and a paid-up capital of ₹41.28 Cr. Formerly known as Mankind Pharma Private Limited. It is led by directors including Vijaya Sampath and Bharat Anand.
Last AGM: 07 August 2025. Financial statements filed for year ended 31 March 2025. Office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020.
As per the financials filed for FY 2025, the company reported a revenue of ₹12,744 Cr, a growth of 21% compared to the previous year.
The company has a workforce of approximately 19,928 employees as per the latest available data. Its group structure includes 22 subsidiaries.
The company is associated with 3 brands - Mediforce Healthcare, Manforce Condoms, Mankind Pharma. As per MCA filings, the company has open charges of ₹6,376 Cr and satisfied charges of ₹6,387.37 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mankindpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Mankind Pharma Limited
Mankind Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74899DL1991PLC044843, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74899DL1991PLC044843 | Current |
| U74899DL1991PLC044843 | Previous |
| U74899DL1991PTC044843 | Previous |
Associated Brands with Mankind Pharma Limited
Mankind Pharma Limited operates multiple associated brands including Mediforce Healthcare, Manforce Condoms, and Mankind Pharma. These brands represent Mankind Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures and distributes a range of medicines and healthcare products. | mediforcehealthcare.com | |
| Condom manufacturing and sexual health resources in India. | manforcecondoms.com | |
| Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | mankindpharma.com |
Competitors & Alternatives of Mankind Pharma Limited
Brands and companies operating in the same space as Mankind Pharma Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
CoreRx
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
MedPharm
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Business Activity of Mankind Pharma Limited
Mankind Pharma Limited is engaged in principal business activities including trade and manufacturing, with detailed activities including wholesale trading, chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Mankind Pharma Limited
Mankind Pharma Limited is audited by S.R. Batliboi & Co. LLP (ICAI peer reviewed, certificate valid till 2027-07-31); Bhagi Bhardwaj Gaur & Co (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| S.R. Batliboi & Co. LLP (ICAI peer reviewed, certificate valid till 2027-07-31); Bhagi Bhardwaj Gaur & Co (ICAI peer reviewed, certificate valid till 2028-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Mankind Pharma Limited
Mankind Pharma Limited is currently managed by 10 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Vijaya Sampath
Also directs:
Mankind Pharma Limited, Ingersoll-Rand (India) Limited, Craftsman Automation Limited and 5 more
|
Director | 01 Aug 2022 | 3 Years 11 Months | Current |
|
Bharat Anand
Also directs:
Mankind Pharma Limited, Kindcare Foundation, Bharat Serums And Vaccines Limited and 5 more
|
Director | 31 Aug 2018 | 7 Years 10 Months | Current |
|
Sheetal Arora
Also directs:
Mankind Pharma Limited, Pavi Buildwell Private Limited, Kindcare Foundation and 5 more
|
Whole-Time Director | 21 Sep 2007 | 18 Years 9 Months | Current |
|
Satish Kumar Sharma
Also directs:
Mankind Pharma Limited, Mankind Consumer Products Private Limited, Appian Properties Private Limited and 5 more
|
Whole-Time Director | 23 Sep 2016 | 9 Years 9 Months | Current |
| Vivek Kalra | Director | 01 Aug 2022 | 3 Years 11 Months | Current |
|
Rajeev Juneja
Also directs:
Mankind Pharma Limited, Appian Associates Infrastructure Private Limited, Pavi Buildwell Private Limited and 5 more
|
Managing Director | 22 Dec 1992 | 33 Years 6 Months | Current |
Financials of Mankind Pharma Limited FY 2026 filings available
Mankind Pharma Limited reported revenue of ₹14,278 Cr (up 16.96% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹14,278 Cr | ₹12,207 Cr | ₹10,335 Cr | ₹8,749.43 Cr |
| Other Income | ₹358.79 Cr | ₹536.79 Cr | ₹280.86 Cr | ₹128.57 Cr |
| Total Income | ₹14,636 Cr | ₹12,744 Cr | ₹10,616 Cr | ₹8,878 Cr |
| Cost of Materials Consumed | ₹2,288.03 Cr | ₹2,016.35 Cr | ₹1,853.52 Cr | ₹1,813.66 Cr |
| Purchases of Stock-in-Trade | ₹1,727.97 Cr | ₹1,655.69 Cr | ₹1,409.85 Cr | ₹809.24 Cr |
| Changes in Inventories | ₹36.12 Cr | -₹183 Cr | -₹53.67 Cr | ₹290.74 Cr |
| Employee Benefit Expense | ₹3,183.9 Cr | ₹2,692.37 Cr | ₹2,274.73 Cr | ₹1,918.47 Cr |
| Finance Costs | ₹639.28 Cr | ₹429.41 Cr | ₹33.53 Cr | ₹44.47 Cr |
| Depreciation & Amortisation | ₹886.18 Cr | ₹621.22 Cr | ₹398.25 Cr | ₹325.92 Cr |
| Other Expenses | ₹3,424.21 Cr | ₹3,008.1 Cr | ₹2,315.28 Cr | ₹2,016.68 Cr |
| Total Expenses | ₹12,186 Cr | ₹10,240 Cr | ₹8,231.49 Cr | ₹7,219.18 Cr |
| Profit Before Exceptional Items & Tax | ₹2,450.74 Cr | ₹2,504.09 Cr | ₹2,384.14 Cr | ₹1,658.81 Cr |
| Exceptional Items | -₹129.75 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2,320.99 Cr | ₹2,504.09 Cr | ₹2,384.14 Cr | ₹1,658.81 Cr |
| Total Tax Expense | ₹394.58 Cr | ₹509.74 Cr | ₹457.59 Cr | ₹361.56 Cr |
| Net Profit | ₹1,938.1 Cr | ₹2,011.12 Cr | ₹1,941.77 Cr | ₹1,309.68 Cr |
| attributable to Owners | ₹1,912.93 Cr | ₹1,986.43 Cr | ₹1,912.9 Cr | ₹1,281.86 Cr |
| attributable to NCI | ₹25.17 Cr | ₹20.16 Cr | ₹28.88 Cr | ₹27.82 Cr |
| Other Comprehensive Income | ₹57.04 Cr | -₹8.29 Cr | -₹8.02 Cr | -₹1.89 Cr |
| Total Comprehensive Income | ₹1,995.14 Cr | ₹2,002.83 Cr | ₹1,933.75 Cr | ₹1,307.79 Cr |
| EBITDA (computed) | ₹3,976.2 Cr | ₹3,554.72 Cr | ₹2,815.93 Cr | ₹2,029.2 Cr |
| Basic EPS | ₹46.35 | ₹49.17 | ₹47.75 | ₹32.00 |
| Diluted EPS | ₹46.28 | ₹49.08 | ₹47.68 | ₹32.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹28,080 Cr | ₹27,760 Cr | ₹11,963 Cr | ₹9,715.45 Cr |
| Non-current Assets | ₹20,937 Cr | ₹20,582 Cr | ₹5,313.04 Cr | ₹5,285.06 Cr |
| Current Assets | ₹7,139.69 Cr | ₹7,175.06 Cr | ₹6,647.51 Cr | ₹4,427.07 Cr |
| Property, Plant & Equipment | ₹2,959.56 Cr | ₹2,907.82 Cr | ₹2,931.59 Cr | ₹2,523.8 Cr |
| Inventories | ₹2,144.48 Cr | ₹2,093.71 Cr | ₹1,553.46 Cr | ₹1,498.46 Cr |
| Trade Receivables | ₹1,729.51 Cr | ₹1,538.34 Cr | ₹848.28 Cr | ₹576.42 Cr |
| Cash & Equivalents | ₹391.69 Cr | ₹407.36 Cr | ₹382.01 Cr | ₹304.82 Cr |
| Equity (Net Worth) | ₹16,561 Cr | ₹14,568 Cr | ₹9,575.79 Cr | ₹7,623.29 Cr |
| Equity Share Capital | ₹41.28 Cr | ₹41.26 Cr | ₹40.06 Cr | ₹40.06 Cr |
| Borrowings (Non-current) | ₹2,892.66 Cr | ₹5,540.22 Cr | ₹32.58 Cr | ₹28.32 Cr |
| Borrowings (Current) | ₹3,418.88 Cr | ₹2,971.23 Cr | ₹174.59 Cr | ₹142.05 Cr |
| Total Debt (computed) | ₹6,311.54 Cr | ₹8,511.45 Cr | ₹207.17 Cr | ₹170.37 Cr |
| Current Liabilities | ₹6,507.25 Cr | ₹5,663.56 Cr | ₹2,119.73 Cr | ₹1,863.14 Cr |
| Total Liabilities | ₹11,518 Cr | ₹13,191 Cr | ₹2,387.47 Cr | ₹2,092.16 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹3,121.29 Cr | ₹2,413.38 Cr | ₹2,152.45 Cr | ₹1,813.3 Cr |
| Investing Cash Flow | -₹196.42 Cr | -₹12,683 Cr | -₹2,081.69 Cr | -₹1,054.13 Cr |
| Financing Cash Flow | -₹2,952.69 Cr | ₹10,290 Cr | ₹5.27 Cr | -₹739.73 Cr |
| Capital Expenditure | ₹625.96 Cr | ₹460.79 Cr | ₹315.33 Cr | ₹789.02 Cr |
| Free Cash Flow (computed) | ₹2,495.33 Cr | ₹1,952.59 Cr | ₹1,837.11 Cr | ₹1,024.28 Cr |
| Dividends Paid | ₹41.27 Cr | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹12.19 Cr | ₹21.87 Cr | ₹77.19 Cr | ₹21.76 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹3,442.93 Cr | ₹3,567.2 Cr | ₹3,697.16 Cr | ₹3,570.35 Cr | ₹3,079.37 Cr | ₹3,230 Cr | ₹3,076.51 Cr | ₹2,893.42 Cr | ₹2,441.1 Cr | ₹2,606.96 Cr | ₹2,708.1 Cr | ₹2,578.62 Cr |
| Other Income | ₹114.29 Cr | ₹72.75 Cr | ₹91.87 Cr | ₹79.88 Cr | ₹251.33 Cr | ₹77.32 Cr | ₹109.43 Cr | ₹100.6 Cr | ₹92.13 Cr | ₹70.13 Cr | ₹59.98 Cr | ₹58.62 Cr |
| Total Income | ₹3,557.22 Cr | ₹3,639.95 Cr | ₹3,789.03 Cr | ₹3,650.23 Cr | ₹3,330.7 Cr | ₹3,307.32 Cr | ₹3,185.94 Cr | ₹2,994.02 Cr | ₹2,533.23 Cr | ₹2,677.09 Cr | ₹2,768.08 Cr | ₹2,637.24 Cr |
| Cost of Materials Consumed | ₹554.95 Cr | ₹553.04 Cr | ₹594.36 Cr | ₹585.68 Cr | ₹554.25 Cr | ₹536.11 Cr | ₹461.99 Cr | ₹472.98 Cr | ₹436.34 Cr | ₹456.74 Cr | ₹473.74 Cr | ₹486.69 Cr |
| Purchases of Stock-in-Trade | ₹498.36 Cr | ₹411.67 Cr | ₹412.97 Cr | ₹404.97 Cr | ₹411.12 Cr | ₹387.3 Cr | ₹424.28 Cr | ₹432.99 Cr | ₹342.29 Cr | ₹352.79 Cr | ₹363.33 Cr | ₹351.45 Cr |
| Changes in Inventories | -₹94.94 Cr | ₹13.28 Cr | ₹54.84 Cr | ₹62.94 Cr | -₹89.99 Cr | ₹11.81 Cr | -₹11.38 Cr | -₹93.44 Cr | -₹41.34 Cr | ₹18.05 Cr | -₹12.21 Cr | -₹18.17 Cr |
| Employee Benefit Expense | ₹751.6 Cr | ₹823.71 Cr | ₹825.18 Cr | ₹783.41 Cr | ₹715.8 Cr | ₹709.71 Cr | ₹646.43 Cr | ₹633.78 Cr | ₹581.51 Cr | ₹568.35 Cr | ₹571.96 Cr | ₹552.91 Cr |
| Finance Costs | ₹141.75 Cr | ₹157.2 Cr | ₹169.68 Cr | ₹170.65 Cr | ₹190.54 Cr | ₹220.93 Cr | ₹7.1 Cr | ₹10.91 Cr | ₹9.38 Cr | ₹9.19 Cr | ₹8.62 Cr | ₹6.34 Cr |
| Depreciation & Amortisation | ₹223.08 Cr | ₹222.6 Cr | ₹221.82 Cr | ₹218.68 Cr | ₹230.87 Cr | ₹192.3 Cr | ₹105.62 Cr | ₹107.74 Cr | ₹104.69 Cr | ₹109.73 Cr | ₹96.48 Cr | ₹87.35 Cr |
| Other Expenses | ₹803.08 Cr | ₹846.07 Cr | ₹888.48 Cr | ₹886.58 Cr | ₹805 Cr | ₹755.27 Cr | ₹705.15 Cr | ₹765.35 Cr | ₹531.2 Cr | ₹604.51 Cr | ₹628.63 Cr | ₹550.93 Cr |
| Total Expenses | ₹2,877.88 Cr | ₹3,027.57 Cr | ₹3,167.33 Cr | ₹3,112.91 Cr | ₹2,817.59 Cr | ₹2,813.43 Cr | ₹2,339.19 Cr | ₹2,330.31 Cr | ₹1,964.06 Cr | ₹2,119.36 Cr | ₹2,130.56 Cr | ₹2,017.5 Cr |
| Profit Before Exceptional Items & Tax | ₹679.34 Cr | ₹612.38 Cr | ₹621.7 Cr | ₹537.32 Cr | ₹513.11 Cr | ₹493.89 Cr | ₹846.75 Cr | ₹663.71 Cr | ₹569.16 Cr | ₹557.73 Cr | ₹637.52 Cr | ₹619.74 Cr |
| Exceptional Items | -₹23.16 Cr | -₹106.59 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹656.18 Cr | ₹505.79 Cr | ₹621.7 Cr | ₹537.32 Cr | ₹513.11 Cr | ₹493.89 Cr | ₹846.75 Cr | ₹663.71 Cr | ₹569.16 Cr | ₹557.73 Cr | ₹637.52 Cr | ₹619.74 Cr |
| Total Tax Expense | ₹99.75 Cr | ₹95.12 Cr | ₹103.84 Cr | ₹95.87 Cr | ₹86.44 Cr | ₹112.81 Cr | ₹190.44 Cr | ₹124.55 Cr | ₹94.98 Cr | ₹102.52 Cr | ₹129.81 Cr | ₹130.28 Cr |
| Net Profit | ₹559.42 Cr | ₹413.88 Cr | ₹520.18 Cr | ₹444.62 Cr | ₹424.65 Cr | ₹384.52 Cr | ₹658.88 Cr | ₹543.07 Cr | ₹476.59 Cr | ₹459.81 Cr | ₹511.18 Cr | ₹494.19 Cr |
| attributable to Owners | ₹554.35 Cr | ₹408.75 Cr | ₹511.51 Cr | ₹438.32 Cr | ₹425.11 Cr | ₹380.23 Cr | ₹653.47 Cr | ₹536.49 Cr | ₹471.24 Cr | ₹453.76 Cr | ₹501.03 Cr | - |
| attributable to NCI | ₹5.07 Cr | ₹5.13 Cr | ₹8.67 Cr | ₹6.3 Cr | ₹3.88 Cr | ₹4.29 Cr | ₹5.41 Cr | ₹6.58 Cr | ₹5.35 Cr | ₹6.05 Cr | ₹10.15 Cr | - |
| Other Comprehensive Income | ₹28.94 Cr | ₹5.95 Cr | ₹22.91 Cr | -₹76 Lakh | -₹13.92 Cr | ₹10.93 Cr | -₹2.2 Cr | -₹3.1 Cr | -₹8.36 Cr | ₹5.75 Cr | -₹2.12 Cr | -₹3.3 Cr |
| Total Comprehensive Income | ₹588.36 Cr | ₹419.83 Cr | ₹543.09 Cr | ₹443.86 Cr | ₹410.73 Cr | ₹395.45 Cr | ₹656.68 Cr | ₹539.97 Cr | ₹468.23 Cr | ₹465.57 Cr | ₹509.06 Cr | ₹490.89 Cr |
| EBITDA (computed) | ₹1,044.17 Cr | ₹992.18 Cr | ₹1,013.2 Cr | ₹926.65 Cr | ₹934.52 Cr | ₹907.12 Cr | ₹959.47 Cr | ₹782.36 Cr | ₹683.23 Cr | ₹676.64 Cr | ₹742.62 Cr | ₹713.43 Cr |
| Basic EPS | ₹13.44 | ₹9.90 | ₹12.39 | ₹10.62 | ₹10.30 | ₹9.45 | ₹16.31 | ₹13.39 | ₹11.76 | ₹11.33 | ₹12.51 | ₹12.15 |
| Diluted EPS | ₹13.41 | ₹9.89 | ₹12.38 | ₹10.60 | ₹10.29 | ₹9.44 | ₹16.28 | ₹13.37 | ₹11.74 | ₹11.31 | ₹12.49 | ₹12.14 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹10,421 Cr | ₹9,497.8 Cr | ₹9,264.81 Cr | ₹8,127.15 Cr |
| Other Income | ₹326.1 Cr | ₹493.21 Cr | ₹266.64 Cr | ₹162.78 Cr |
| Total Income | ₹10,747 Cr | ₹9,991.01 Cr | ₹9,531.45 Cr | ₹8,289.94 Cr |
| Cost of Materials Consumed | ₹860.52 Cr | ₹800.43 Cr | ₹861.74 Cr | ₹711.05 Cr |
| Purchases of Stock-in-Trade | ₹1,729.28 Cr | ₹1,809.96 Cr | ₹2,071.92 Cr | ₹1,865.82 Cr |
| Changes in Inventories | ₹35.37 Cr | -₹13.5 Cr | -₹25.36 Cr | ₹267.89 Cr |
| Employee Benefit Expense | ₹2,367.04 Cr | ₹2,131.67 Cr | ₹1,982.1 Cr | ₹1,701.38 Cr |
| Finance Costs | ₹562.21 Cr | ₹371.76 Cr | ₹14.57 Cr | ₹27.75 Cr |
| Depreciation & Amortisation | ₹428.57 Cr | ₹378.01 Cr | ₹317.61 Cr | ₹269.58 Cr |
| Other Expenses | ₹2,343.05 Cr | ₹2,206.69 Cr | ₹2,049.3 Cr | ₹1,883.64 Cr |
| Total Expenses | ₹8,326.04 Cr | ₹7,685.02 Cr | ₹7,271.88 Cr | ₹6,727.1 Cr |
| Profit Before Exceptional Items & Tax | ₹2,421.24 Cr | ₹2,305.99 Cr | ₹2,259.57 Cr | ₹1,562.84 Cr |
| Exceptional Items | -₹106.24 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2,315 Cr | ₹2,305.99 Cr | ₹2,259.57 Cr | ₹1,562.84 Cr |
| Total Tax Expense | ₹277.44 Cr | ₹421.74 Cr | ₹436.16 Cr | ₹314.58 Cr |
| Net Profit | ₹2,037.56 Cr | ₹1,945.48 Cr | ₹1,823.41 Cr | ₹1,248.26 Cr |
| Other Comprehensive Income | ₹28.61 Cr | ₹4.98 Cr | -₹6.7 Cr | -₹4.86 Cr |
| Total Comprehensive Income | ₹2,066.17 Cr | ₹1,950.46 Cr | ₹1,816.71 Cr | ₹1,243.4 Cr |
| EBITDA (computed) | ₹3,412.02 Cr | ₹3,055.76 Cr | ₹2,591.74 Cr | ₹1,860.16 Cr |
| Basic EPS | ₹49.37 | ₹46.64 | ₹45.52 | ₹31.16 |
| Diluted EPS | ₹49.30 | ₹46.56 | ₹45.45 | ₹31.16 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹24,625 Cr | ₹23,828 Cr | ₹11,418 Cr | ₹9,371.12 Cr |
| Non-current Assets | ₹20,335 Cr | ₹19,032 Cr | ₹5,858.79 Cr | ₹5,758.8 Cr |
| Current Assets | ₹4,287.98 Cr | ₹4,794.11 Cr | ₹5,556.22 Cr | ₹3,609.14 Cr |
| Property, Plant & Equipment | ₹1,938.85 Cr | ₹1,941.45 Cr | ₹1,811.33 Cr | ₹1,435.81 Cr |
| Inventories | ₹1,087.84 Cr | ₹1,090.98 Cr | ₹1,075.59 Cr | ₹1,032.22 Cr |
| Trade Receivables | ₹1,163.63 Cr | ₹894.67 Cr | ₹749.47 Cr | ₹492.64 Cr |
| Cash & Equivalents | ₹87.66 Cr | ₹200.29 Cr | ₹189.2 Cr | ₹134.13 Cr |
| Equity (Net Worth) | ₹16,397 Cr | ₹14,640 Cr | ₹9,623.81 Cr | ₹7,783.91 Cr |
| Equity Share Capital | ₹41.28 Cr | ₹41.26 Cr | ₹40.06 Cr | ₹40.06 Cr |
| Borrowings (Non-current) | ₹2,529.21 Cr | ₹4,945.93 Cr | ₹5.95 Cr | ₹3.23 Cr |
| Borrowings (Current) | ₹3,041.57 Cr | ₹2,308.19 Cr | ₹2.62 Cr | ₹1.46 Cr |
| Total Debt (computed) | ₹5,570.78 Cr | ₹7,254.12 Cr | ₹8.56 Cr | ₹4.69 Cr |
| Current Liabilities | ₹5,473.19 Cr | ₹4,091.52 Cr | ₹1,593.36 Cr | ₹1,419.09 Cr |
| Total Liabilities | ₹8,228.37 Cr | ₹9,188.05 Cr | ₹1,793.9 Cr | ₹1,587.21 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹2,751.99 Cr | ₹2,322.16 Cr | ₹1,982.97 Cr | ₹1,798.99 Cr |
| Investing Cash Flow | -₹387.96 Cr | -₹12,115 Cr | -₹1,919.12 Cr | -₹1,040.61 Cr |
| Financing Cash Flow | -₹2,476.92 Cr | ₹9,783.47 Cr | -₹8.68 Cr | -₹710.41 Cr |
| Capital Expenditure | ₹337.16 Cr | ₹298.43 Cr | ₹188.91 Cr | ₹548.36 Cr |
| Free Cash Flow (computed) | ₹2,414.83 Cr | ₹2,023.73 Cr | ₹1,794.06 Cr | ₹1,250.62 Cr |
| Dividends Paid | ₹41.27 Cr | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹113.02 Cr | -₹11.33 Cr | ₹55.07 Cr | ₹47.96 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,581.82 Cr | ₹2,632.68 Cr | ₹2,608.78 Cr | ₹2,541.36 Cr | ₹2,126.59 Cr | ₹2,396.57 Cr | ₹2,529.74 Cr | ₹2,403.26 Cr | ₹2,152.69 Cr | ₹2,358.57 Cr | ₹2,453.35 Cr | ₹2,300.21 Cr |
| Other Income | ₹126.7 Cr | ₹56.52 Cr | ₹77.67 Cr | ₹64.22 Cr | ₹219.32 Cr | ₹69.82 Cr | ₹105.76 Cr | ₹94.83 Cr | ₹83.85 Cr | ₹67.23 Cr | ₹58.12 Cr | ₹57.44 Cr |
| Total Income | ₹2,708.52 Cr | ₹2,689.2 Cr | ₹2,686.45 Cr | ₹2,605.58 Cr | ₹2,345.91 Cr | ₹2,466.39 Cr | ₹2,635.5 Cr | ₹2,498.09 Cr | ₹2,236.54 Cr | ₹2,425.8 Cr | ₹2,511.46 Cr | ₹2,357.65 Cr |
| Cost of Materials Consumed | ₹203.58 Cr | ₹201.14 Cr | ₹230.46 Cr | ₹224.76 Cr | ₹216.76 Cr | ₹179.72 Cr | ₹182.12 Cr | ₹204.24 Cr | ₹213.15 Cr | ₹205.21 Cr | ₹229.96 Cr | ₹213.41 Cr |
| Purchases of Stock-in-Trade | ₹419.66 Cr | ₹452.66 Cr | ₹432.84 Cr | ₹414.47 Cr | ₹384.25 Cr | ₹445.6 Cr | ₹484.31 Cr | ₹503.96 Cr | ₹477.13 Cr | ₹500.36 Cr | ₹538.46 Cr | ₹555.98 Cr |
| Changes in Inventories | -₹49.98 Cr | ₹8.14 Cr | ₹47.46 Cr | ₹30.41 Cr | -₹43.53 Cr | ₹34.08 Cr | ₹36.94 Cr | -₹21.71 Cr | -₹67.33 Cr | ₹24.14 Cr | -₹2.08 Cr | ₹19.91 Cr |
| Employee Benefit Expense | ₹550.85 Cr | ₹617.33 Cr | ₹600.29 Cr | ₹584.87 Cr | ₹536.75 Cr | ₹521.79 Cr | ₹525.86 Cr | ₹522.1 Cr | ₹507.93 Cr | ₹492.68 Cr | ₹500.29 Cr | ₹481.2 Cr |
| Finance Costs | ₹125.28 Cr | ₹138.37 Cr | ₹147.2 Cr | ₹146.7 Cr | ₹162.25 Cr | ₹199.47 Cr | ₹1.92 Cr | ₹6.26 Cr | ₹4.03 Cr | ₹4.26 Cr | ₹4.31 Cr | ₹1.97 Cr |
| Depreciation & Amortisation | ₹109.43 Cr | ₹107.69 Cr | ₹99.03 Cr | ₹96.93 Cr | ₹105.24 Cr | ₹87.03 Cr | ₹85.42 Cr | ₹83.4 Cr | ₹82.29 Cr | ₹89.73 Cr | ₹77.04 Cr | ₹68.54 Cr |
| Other Expenses | ₹538.87 Cr | ₹575.16 Cr | ₹604.54 Cr | ₹613.78 Cr | ₹555.44 Cr | ₹474.45 Cr | ₹548.48 Cr | ₹622.47 Cr | ₹474.47 Cr | ₹533.07 Cr | ₹551.52 Cr | ₹490.24 Cr |
| Total Expenses | ₹1,897.69 Cr | ₹2,100.49 Cr | ₹2,161.82 Cr | ₹2,111.92 Cr | ₹1,917.16 Cr | ₹1,942.14 Cr | ₹1,865.05 Cr | ₹1,920.72 Cr | ₹1,691.68 Cr | ₹1,849.45 Cr | ₹1,899.5 Cr | ₹1,831.25 Cr |
| Profit Before Exceptional Items & Tax | ₹810.83 Cr | ₹588.71 Cr | ₹524.63 Cr | ₹493.66 Cr | ₹428.75 Cr | ₹524.25 Cr | ₹770.45 Cr | ₹577.37 Cr | ₹544.86 Cr | ₹576.35 Cr | ₹611.96 Cr | ₹526.39 Cr |
| Exceptional Items | -₹22.82 Cr | -₹83.42 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹788.01 Cr | ₹505.29 Cr | ₹524.63 Cr | ₹493.66 Cr | ₹428.75 Cr | ₹524.25 Cr | ₹770.45 Cr | ₹577.37 Cr | ₹544.86 Cr | ₹576.35 Cr | ₹611.96 Cr | ₹526.39 Cr |
| Total Tax Expense | ₹74.4 Cr | ₹55.82 Cr | ₹65.73 Cr | ₹80.9 Cr | ₹46.29 Cr | ₹107.87 Cr | ₹168.01 Cr | ₹93.12 Cr | ₹90.69 Cr | ₹89.28 Cr | ₹139.08 Cr | ₹117.11 Cr |
| Net Profit | ₹713.61 Cr | ₹449.47 Cr | ₹458.9 Cr | ₹412.76 Cr | ₹382.46 Cr | ₹416.38 Cr | ₹634.43 Cr | ₹513.49 Cr | ₹454.17 Cr | ₹487.07 Cr | ₹472.88 Cr | ₹409.28 Cr |
| Other Comprehensive Income | ₹8.71 Cr | ₹3.06 Cr | ₹15.79 Cr | ₹1.06 Cr | -₹3.27 Cr | ₹9.41 Cr | ₹17 Lakh | -₹1.34 Cr | -₹7.38 Cr | ₹6.93 Cr | -₹3.56 Cr | -₹2.69 Cr |
| Total Comprehensive Income | ₹722.32 Cr | ₹452.53 Cr | ₹474.69 Cr | ₹413.82 Cr | ₹379.19 Cr | ₹425.79 Cr | ₹634.6 Cr | ₹512.15 Cr | ₹446.79 Cr | ₹494 Cr | ₹469.33 Cr | ₹406.59 Cr |
| EBITDA (computed) | ₹1,045.54 Cr | ₹834.77 Cr | ₹770.86 Cr | ₹737.29 Cr | ₹696.24 Cr | ₹810.75 Cr | ₹857.79 Cr | ₹667.03 Cr | ₹631.19 Cr | ₹670.34 Cr | ₹693.31 Cr | ₹596.9 Cr |
| Basic EPS | ₹17.29 | ₹10.89 | ₹11.12 | ₹10.00 | ₹9.27 | ₹10.35 | ₹15.04 | ₹12.09 | ₹11.34 | ₹12.16 | ₹11.80 | ₹10.22 |
| Diluted EPS | ₹17.27 | ₹10.87 | ₹11.10 | ₹9.99 | ₹9.25 | ₹10.33 | ₹15.01 | ₹12.07 | ₹11.32 | ₹12.14 | ₹11.79 | ₹10.21 |
Shareholding Pattern of Mankind Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 72.66%, foreign institutional investors hold 10.24%, domestic institutional investors hold 14.46%, retail and other public shareholders hold 2.64% of Mankind Pharma Limited. The company had 177,606 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 72.66% | 72.66% | 72.67% | 72.68% | 72.70% | 72.71% |
| Public | 27.34% | 27.34% | 27.33% | 27.32% | 27.30% | 27.29% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 72.66% | 72.70% | 74.88% |
| Public | 27.34% | 27.30% | 25.12% |
| Promoter change (YoY, %pts) | -0.04 | -2.18 | - |
Board & Governance of Mankind Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Mankind Pharma Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Ramesh Juneja.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Ramesh Juneja | Executive Director · Chairperson | 1991-07-03 | 1 |
| Rajeev Juneja | Executive Director · MD | 1992-12-22 | 1 |
| Sheetal Arora | Executive Director · CEO | 2007-09-21 | 1 |
| Satish Kumar Sharma | Executive Director | 2016-09-23 | 1 |
| Tilokchand Punamchand Ostwal | Non-Executive - Independent Director | 2020-01-01 | 2 |
| Bharat Anand | Non-Executive - Independent Director | 2018-08-31 | 5 |
| Vijaya Sampath | Non-Executive - Independent Director | 2022-08-01 | 5 |
| Vivek Santokh Kalra | Non-Executive - Independent Director | 2022-08-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Vijaya Sampath (Chairperson), Tilokchand Punamchand Ostwal, Bharat Anand, Vivek Santokh Kalra |
| Nomination and remuneration committee | Tilokchand Punamchand Ostwal (Chairperson), Vijaya Sampath, Bharat Anand |
| Stakeholders Relationship Committee | Tilokchand Punamchand Ostwal (Chairperson), Sheetal Arora, Vivek Santokh Kalra |
| Risk Management Committee | Sheetal Arora (Chairperson), Vijaya Sampath, Bharat Anand, Ashutosh Dhawan |
| Corporate Social Responsibility Committee | Ramesh Juneja (Chairperson), Sheetal Arora, Bharat Anand |
Group Structure of Mankind Pharma Limited
Mankind Pharma Limited has 22 subsidiary companies and 2 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Mankind Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Qualitek Starch Private Limited | U15134HP2019PTC007684 | - |
| Mankind Medicare Private Limited | U21002DL2023PTC419826 | - |
| Appian Properties Private Limited | U24100DL2017PTC321898 | - |
| Mankind Life Sciences Private Limited | U24100DL2020PTC369904 | - |
| Mankind Consumer Healthcare Private Limited | U24230DL2021PTC388536 | - |
| Pharmaforce Excipients Private Limited | U24230HP2019PTC007703 | - |
Showing major subsidiaries. Total: 22.
Charges & Borrowings of Mankind Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Nov 2025 | Citi Bank N.A. | ₹106 Cr | Open |
| 14 Nov 2024 | Others | ₹1,250 Cr | Open |
| 14 Nov 2024 | Others | ₹1,250 Cr | Open |
| 14 Nov 2024 | Others | ₹2,500 Cr | Open |
| 14 Oct 2024 | State Bank of India | ₹300 Cr | Open |
Total charge records: 38 View all charges
Employees and EPFO Compliance at Mankind Pharma Limited
Mankind Pharma Limited has a workforce of 19,928 employees as of Oct 10, 2025.
Employee Count & EPFO Data of Mankind Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Mankind Pharma Limited
GSTIN & GST Filing Data of Mankind Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Mankind Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Mankind Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Mankind Pharma Limited
MSME Payment Delays by Mankind Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Mankind Pharma Limited
Subsidiaries & Group Companies of Mankind Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Mankind Pharma Limited with ownership details.
MCA Filings & Documents of Mankind Pharma Limited
MCA Filings & Documents of Mankind Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Mankind Pharma Limited
Recent News on Mankind Pharma Limited
Frequently Asked Questions about Mankind Pharma Limited
Mankind Pharma Limited is an active public limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 03 July 1991 (35+ years old) and is registered under CIN L74899DL1991PLC044843. The company has 19,928 employees.
Mankind Pharma Limited reported revenue of ₹12,744 Cr for FY 2025 (up 21.00% YoY).
The current directors of Mankind Pharma Limited are:
- Vijaya Sampath
- Bharat Anand
- Sheetal Arora
- Ashutosh Dhawan
- Satish Kumar Sharma
- Vivek Kalra
- Rajeev Juneja
- Ramesh Juneja
- Hitesh Kumar Jain
- Tilokchand Punamchand Ostwal
The primary industry of Mankind Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Mankind Pharma Limited is a listed company.
Mankind Pharma Limited can be reached at the registered office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020, or through the website mankindpharma.com.